{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045112","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.160548+00:00","generated_at":"2026-05-30T05:23:45.405556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint","bullets":["Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).","Non-GAAP EPS $0.06 vs $0.05; GAAP loss per share $0.07 vs $0.12.","Pain Treatments +16.7%, Surgical Solutions +18.5%, Restorative Therapies +1.2% (all YoY).","Agreed to divest Advanced Rehabilitation Business for up to $45M; close expected late 2024/early 2025; proceeds to reduce debt.","FY2024 guidance: net sales $562-567M, Adj. EBITDA $104-107M, Non-GAAP EPS $0.40-0.42 (midpoints raised)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045112","json":"https://secwatch.observer/filing/0001628280-24-045112.json","markdown":"https://secwatch.observer/filing/0001628280-24-045112.md","text":"https://secwatch.observer/filing/0001628280-24-045112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024045112/0001628280-24-045112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024045112/bvs-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:23:45.405556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}